Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 601–700 of 1,871
Role of obesity in chronic kidney disease progression
Dada, A., Ren, J. Y., Shi, Y., & Nistala, R. (2025) · Current Research in Physiology · doi:10.1016/j.crphys.2025.100172 · Cited by 6
Han, S., Yang, Y., Liu, Z., Liu, Y., Xing, B., Wang, X., Yu, J., Ping, F., Li, W., Xu, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70692 · Cited by 8
“Moreover, as several large randomised clinical trials (RCTs) of GLP-1 RAs have recently been published, the relevant evidence requires updating [19, 20].”
Hsiao, C.-C., Chen, M., Liu, C. Y., Chan, C.-Y., Fang, Y.-W., Liou, H., & Tsai, M. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf172 · Cited by 11
Doumani, G., Theofilis, P., Vordoni, A., Thymis, V., Liapis, G., Smirloglou, D., & Kalaitzidis, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178224 · Cited by 9
“According to the results of the latest study “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes” (FLOW) 1.0 mg once-weekly dose of semaglutide lowered the risk of major kidney and cardiovascular endpoints, and death from any cause [53].”
InfluentialScheen, A. J. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2527092 · Cited by 6
“However, a recent meta-analysis, which included data issued from newer RCTs with semaglutide [47,57], found evidence that GLP-1RAs significantly reduce clinically important kidney events and kidney failure [46].”
Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC) (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004559 · Cited by 8
“…[36] from a baseline of 2.9–7.4 per 1,000 person-years from observational cohorts [33,34]), and a 20% reduction in all-cause mortality (hazard ratio, 0.80; 95% CI, 0.67–0.95 [43], with baseline mortality for people with diabetes modeled as 1.769 * exp^(0.0565 * age) per observational studies [35]).”
InfluentialHealth and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss
Sforzo, G. A., Gordon, N. F., Peeke, P. M., & Moore, M. A. (2024) · American Journal of Lifestyle Medicine · doi:10.1177/15598276241302273 · Cited by 8
Lalic, K. S., Popović, L., Lukač, S. S., Rasulić, I., Petakov, A., Krstic, M., Mitrović, M., Jotić, A., & Lalic, N. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111819 · Cited by 5
Bramlage, P., Vijayan, A., Varghese, T. P., Sadanandan, D. M., Lanzinger, S., & Rodriguez, C. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70010 · Cited by 7
Vafeidou, K., Psoma, O., Dimakopoulos, G., Apostolidis, E., Sarvani, A., Gavriilaki, E., Doumas, M. N., Tsimihodimos, V., Kotsa, K., & Koufakis, T. (2025) · Pharmaceuticals · doi:10.3390/ph18060807 · Cited by 5
“GLP-1 RA have demonstrated significant nephroprotective properties in patients with T2D [24].”
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
A geriatrician's approach to managing the complex older adult with obesity
Dewar, S. (2025) · Obesity · doi:10.1002/oby.24267 · Cited by 7
“Furthermore, the results of the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial have shown that semaglutide at a lower dose of 1 mg weekly reduced the risk of clinically important kidney outcomes by 24% while slowing the chronic disease progression [35].”
Palacios, P. C. G., Moscona-Nissan, A., Saucedo, R., & Ferreira‐Hermosillo, A. (2025) · Metabolites · doi:10.3390/metabo15040260 · Cited by 5
“It is recommended to discontinue treatment with GLP-1RAs such as semaglu-tide and tirzepatide at least two months prior to conception [64,68].”
Zhang, J., Li, W., Sun, Z., Wang, Y., Xue, Y., Si, K., Huang, Y., Lv, W., Xu, L., & Wang, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0333672 · Cited by 8
“…trial involving patients with T2D and CKD showed that semaglutide significantly reduced the risk of major events in kidney disease, including the onset of renal failure and the rate of decline in renal function, by 24% compared with the placebo group (Hazard ratio, 0.76; P = 0.0003) [27].”
InfluentialRico-Fontalvo, J. E., Reina, M., Soler, M. J., Unigarro-Palacios, M., Castañeda-González, J. P., Quintero, J. J., Raad-Sarabia, M., de Moraes, T. P., & Daza-Arnedo, R. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-0101en · Cited by 7
“The FLOW study with semaglutide was the first study specifically designed to confirm the renal benefits of this medication in a population of diabetic patients at very high cardiovascular risk 41 .”
MethodChronic Kidney Disease and Cellular Senescence
Morevati, M., Tavenier, J., Scheibye‐Knudsen, M., Houlind, M. B., Hedayati, A., & Hornum, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073205 · Cited by 6
“SGLT-2 inhibitors and GLP-1 receptor agonists are now recognized not only as cardio-renal protective agents but also as modulators of molecular ageing pathways, with SGLT-2 inhibition showing indirect senolytic activity [28–33].”
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Chronic kidney disease in patients with diabetes mellitus: new challenges
Шамхалова, М. Ш., Sukhareva, O. Y., Martynov, S. A., Severina, A. S., Vikulova, O. K., Trubitsyna, N. P., Николаевна, Н. О., Zaytseva, N. V., Shestakova, M. V., Dedov, I. I., et al. (2025) · Diabetes Mellitus · doi:10.14341/dm13268 · Cited by 6
The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus
De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G. (2025) · Nutrients · doi:10.3390/nu17193038 · Cited by 4
“Moreover, certain GLP-1 RAs, such as liraglutide, dulaglutide, and semaglutide in both formulations, have demonstrated CV and renal benefits [66–68].”
Radić, J., Vučković, M., Đogaš, H., Grubić, M., Belančić, A., Tandara, L., Šegvić, L. Š., Novak, I., & Radić, M. (2024) · Medicina · doi:10.3390/medicina60101643 · Cited by 4
Liu, J.-J., Liu, S., Gurung, R. L., Lee, J., Zheng, H., Ang, K., Chan, C., Lee, L. S., Han, S. H. Y., Kovalik, J., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf281 · Cited by 6
Schwartz, A. R., Sosnov, J. A., Brown, J., Delgado, C., Fried, L. F., Tamura, M. K., Morrison, J. W., Navaneethan, S. D., Palevsky, P. M., Rybacki, D. B., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03499 · Cited by 6
Anti-inflammatory effects of GLP1-RA drugs
Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag218 · Cited by 7
Hsiao, F., Hsu, T., Hsieh, Y.-J., Tung, Y., Chen, D., Lin, C., Chen, S., & Chu, P. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.55952 · Cited by 7
Chen, Q., Li, Y., He, H., Xie, Y., Fu, D., Gao, R., Li, N., Fu, S., Yuan, M., Sun, Y., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.002 · Cited by 5
Li, W., Liang, X., Sun, N., & Zhang, D. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01948-7 · Cited by 5
“All studies exhibited random sequence generation [14, 15, 23]- [44].”
Marshall, W. R., Green, D., Sinha, S., & Kalra, P. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1785937 · Cited by 5
Dunn, T. J., Zhu, Y., Gronroos, N. N., Xie, L., Sargent, A., Gamble, C. L., & Billings, L. K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112162 · Cited by 5
Rico-Fontalvo, J. E., Elbert, A. E., Lorca, E., Daza-Arnedo, R., Castellaro, C., Villavicencio, V., Rosa-Diez, G. J., Bonanno-Hidalgo, C., Sánchez-Polo, V., & Correa‐Rotter, R. (2025) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000055 · Cited by 11
Advances in understanding the impact of sex on kidney health and disease
Lees, J. S., Stevens, K. I., Kotwal, S. S., Bruchfeld, A. N., & Levin, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00654-9 · Cited by 6
Keum, Y., Caramori, M. L., Cherney, D. Z. I., Crandall, J. P., de Boer, I. H., Lingvay, I., McGill, J. B., Polsky, S., Pop‐Busui, R., Rossing, P. R., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000567 · Cited by 4
“…transporters, 8 – 13 the nonsteroidal mineralocorticoid receptor-antagonist fi nerenone, 14 and glucagon-like peptide-1 receptor agonists 15 — are available for people with type 2 diabetes, but whether these treatments are effective in individuals with type 1 diabetes mellitus remains…”
Self-citationBonora, B. M., Giaccari, A., Consoli, A., Broglio, F., Avogaro, A., Fadini, G. P., & for the GLIMPLES Study Investigators (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70045 · Cited by 7
“In a dedicated cardiovascular outcomes trial, OW semaglutide has shown the capacity to reduce major adverse cardiovascular events and with reduced rates of renal endpoints [20, 21].”
ANMCO statement: semaglutide in the cardio-nephro-metabolic continuum
Luca, L. D., Bilato, C., Navazio, A., Corda, M., Milli, M., Scicchitano, P., Marco, M. D., Riccio, C., Geraci, G., Iacovoni, A., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf071 · Cited by 4
“51 Recent and growing evidence on cardio-nephro-metabolic outcomes and the availability of an oral formulation are all components that advocate an early treatment strategy, immediately after metformin, on the population with Type 2 diabetes 52 ( Figure 3 ).”
AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists
Wang, X., & Wang, L. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100004 · Cited by 7
“…heterogeneous metabolic disease, and the “multiple-hit” theory for the development of NAFLD is widely accepted, including lipid accumulation in the liver, insulin resistance, oxidative stress, inflammation, genetic and environmental factors, etc. GLP-1RAs have been validated for the treatment of…”
Górriz, J. L., Gil, F. A., López, M. A. B., Soto, A. B., Cabrera, F. J. C., Cisneros, A., Guerrero, S. C., Conejos, M. D., Cabello, I. E., Planelles, M., et al. (2025) · Nefrología · doi:10.1016/j.nefro.2025.02.001 · Cited by 4
Bays, H. E., Varney, C., Alexander, L., Ng, J., Tondt, J., Weber, C., Christensen, S. M., Burridge, K., Brown, C., Bindlish, S., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100283 · Cited by 4
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Abdelrahman, A. M., Awad, A. S., Hasan, I., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247732 · Cited by 4
Thomas, J., Dagan, M., Wang, B. H., Gutman, S., & Kaye, D. M. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013279 · Cited by 10
Spennati, G., Regier, M. C., Ward, H. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.05.669416 · Cited by 4
Curovic, V. R., STOUGAARD, E. B., & Hansen, T. W. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16007 · Cited by 4
“80 The ‘ Albuminuria-lowering effect of dapagliflozin, exenatide numerical but non-significant reduction in UACR of 26% with the combination treatment, 81 which was comparable with results observed in the ‘ Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and…”
Wexler, D. J., Mayberry, L. S., Nelson, L. A., Lema-Driscoll, J., Flores, L. C., Malloy, M. A., MacFadyen, J. G., Shen, J., Zaharris, E., Karanchi, H., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.107332 · Cited by 5
Is Dialysis Nephrology’s Original Sin?
Cohen, A. J. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.01.008 · Cited by 4
Yavorskiy, P., Borrelli, S., Esposito, K., Maiorino, M. I., Petrizzo, M., Nicola, L. D., & Garofalo, C. (2025) · Journal of Nephrology · doi:10.1007/s40620-025-02247-z · Cited by 4
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight lossPreprint
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · medRxiv · doi:10.64898/2026.04.02.26350077 · Cited by 5
Correa-Rotter, R., Wheeler, D. C., & McEwan, P. C. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02950-6 · Cited by 4
“Furthermore, other antidia‑ betic agents, specifically glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) and non‑steroidal mineralocorticoid receptor agonists (ns‑MRAs), have demonstrated clinical efficacy in prevent‑ ing adverse kidney‑related outcomes in patients with both T2D and CKD [7, 8].”
BackgroundSemaglutide and kidney function: direct kidney protection or an artifact?
Ayoub, I. M., Wong, G., & Glassock, R. J. (2024) · Kidney International · doi:10.1016/j.kint.2024.11.003 · Cited by 4
Adeniran, O. F., Nieto, L. M., Amadi, C., Shepherd, K., Kirkpatrick, J., Farah, K., Marwizi, F. M., Alqinai, B., Narvaez, S. I., Mensah, S., et al. (2025) · Obesity · doi:10.1002/oby.70001 · Cited by 6
Gohda, T., Hagiwara, S., Abe, K., HIROSE, H., Shimozawa, K., Kishida, C., Sakuma, H., Adachi, E., Koshida, T., Suzuki, Y., et al. (2024) · Juntendō Igaku/Juntendo igaku · doi:10.14789/ejmj.jmj24-0031-p · Cited by 4
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Roy, A., & Kulkarni, A. V. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000687 · Cited by 9
Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management
Beavers, C. J., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10549-4 · Cited by 10
Chronic kidney disease in the primary care setting: A narrative review
Safdar, F., & Aslam, A. (2025) · Journal of General and Family Medicine · doi:10.1002/jgf2.70054 · Cited by 5
Comprehensive management of chronic kidney disease in the old population
Franco, M. E. P., Puente-García, A., Perez-Belmonte, L. M., Pérez, N., Ellingson, S., & Tornero, F. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2551217 · Cited by 5
Dosda, A., Fauchier, G., Sabbah, N., Fauchier, L., Lecomte, T., & Ducluzeau, P. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101734 · Cited by 7
Shah, J. R., Makwana, B., Panchal, K., Patel, V., Patel, T., Khadke, S., Verma, A., Vivekanandan, S., Kong, Y., Upadhyay, J., et al. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.04.021 · Cited by 6
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study
Sinha, B., & Ghosal, S. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01635-1 · Cited by 4
“…on 3533 patients and followed up for 177 weeks, comparing injectable once weekly semaglutide with placebo, revealed that semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease [8].”
BackgroundAhmed, M., Hashmi, T. M., Shahzad, M., Zia, R., Ashraf, H., Ahmed, R., Rashid, M. O., Greene, S. J., Mentz, R. J., Fudim, M., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag079 · Cited by 4
Care of Adults with Advanced Chronic Kidney Disease
Shrestha, S., Haq, K., Malhotra, D., & Patel, D. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154378 · Cited by 8
“We also note that in the post-hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), intensive anti-hypertensive treatment targeting a systolic BP 120 mmHg was associated with a higher risk of eGFR decline and of kidney failure, though these adverse outcomes were not seen after…”
ResultFadini, G. P., Longato, E., Morieri, M. L., Broglio, F., Aimaretti, G., Russo, G. T., Anichini, R., Ghiani, M., Avogaro, A., Solini, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16569 · Cited by 6
“In conclusion, this study provides compelling real-world evidence that SGLT2i, better than active comparators and GLP-1RA, significantly attenuate the progression of kidney disease in patients with T2D and CKD, reinforcing their role as a foundational therapy in this high-risk population.”
InfluentialHeerspink, H. J. L., van Raalte, D. H., Bjornstad, P., Bunck, M. C. M., Wu, P., Tunali, I., Miličević, Z., & Koeneman, L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf230 · Cited by 9
“In addition, a GLP-1 RA, semaglutide, slowed the progression of CKD and reduced the risks of clinically meaningful kidney and cardiovascular outcomes in patients with T2D and CKD [7 ].”
Nishida, J., Yamakawa, M., Miura, S., & Yasutomi, M. (2025) · CEN Case Reports · doi:10.1007/s13730-025-00990-7 · Cited by 5
“Examination of long-term outcomes and potential synergistic effects with other reno-protective agents, particularly GLP-1 receptor agonists like semaglutide [28], could optimize ADPKD management strategies.”
2025 Update on resistant hypertension in CKD: where do we stand and where do we go?
Schmieder, R. E. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf285 · Cited by 9
Oe, Y., Nomoto, H., Cho, K. Y., Omori, T., Nakamura, K., Takahashi, A., Suzuki, Y., Yoshikawa, J., Kato-Sato, A., Furukawa, S., et al. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251378216 · Cited by 4
Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease
Verma, S., Catarig, A., Houlind, K. C., Ludvik, B. H., Nordanstig, J., Rasouli, N., Sourij, H., Thomas, S., Nørgaard, S. K., & Bonaca, M. P. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.046 · Cited by 5
Cardio‐Kidney‐Metabolic Therapy Use Among Adults With Type 1 Diabetes and Chronic Kidney Disease
Caramori, M. L., REPETTO, E., Perkins, C., Pandey, A., & Rossing, P. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70640 · Cited by 6
Self-citationThe cardiology community begins to embrace obesity as an important target for cardiovascular health
Sattar, N. A., & Rutter, M. K. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004578 · Cited by 4
“Subsequent papers have shown durable weight loss in those who continue to take these medicines [7] with additional evidence for kidney benefits [8,9], added to anticipated benefits of intentional weight loss on multiple other outcomes.”
Protein Intake and Kidney Outcomes in Nondialysis Chronic Kidney Disease Over 15 Years
Beberashvili, I., Baevsky, T., Shmuel, D., Yoles, I., Rosen, M., & Efrati, S. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.9575 · Cited by 6
Temporelli, P. L. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae086 · Cited by 5
“9 Moreover, chronic systemic inflammation plays a fundamental role in the development of atherosclerosis, speeding up the progression of the disease and increasing the risk of acute coronary syndromes and myocardial infarction (MI).”
Current Landscape and Emerging Therapeutic Targets in Diabetic Kidney Disease
Hu, S., Lee, K., He, C., & Fan, Y. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001053 · Cited by 5
Therapy Gaps for Patients with Heart Failure and Reduced Kidney Function: A Prospective Cohort Study
Ma, C.-H., Qi, A. A., Gagnon, L. R., Wang, K., Sadasivan, C., Ghimire, A., Cooper, M. A., Tungsanga, S., Oguaju, B., Vandermeer, B., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.70008 · Cited by 5
“11 Considering these novel data, a better understanding of current practice patterns and gaps in medication use and dose intensity is necessary to promote practices that improve patient outcomes for patients with comorbid kidney dysfunction and HF. 14 In addition, medical treatments in patients…”
InfluentialSeeking Multiorgan Benefits with Cardiovascular–Kidney–Metabolic Drug Therapy
Zannad, F. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2503600 · Cited by 4
Ten tips in lupus nephritis management
Teoh, S. T. Y., Yap, D. Y. H., & Chan, T. M. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae376 · Cited by 4
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Kosaraju, S., & Zhang, R. M. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s473319 · Cited by 8
“5 Therefore, incretins remain a potential therapy to improve kidney outcomes in patients with type 2 diabetes and chronic kidney disease.”
BackgroundWen, S., Xu, C., Yuan, Y., Chen, L., Ren, Y., Xu, Z., Jin, J., Li, J., & Zhou, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1670643 · Cited by 5
Managing Diabetes in Older Adults: Current Approaches in Long-Term Care Facilities
Idrees, T., Castro-Revoredo, I., KANTIPUDI, S. L., & Umpierrez, G. E. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01583-5 · Cited by 6
Olsen, E., Søraas, C. L., Schmieder, R. E., Jamerson, K., MacDonald, T. M., Mancia, G., Heimark, S., Mehlum, M. H., Liestøl, K., Larstorp, A. C. K., et al. (2025) · American Journal of Hypertension · doi:10.1093/ajh/hpaf093 · Cited by 6
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente, V., Beer, B. N., & Savarese, G. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0111 · Cited by 10
“117) CONFIRMATION-HF will assess the efficacy and safety of initiating both a non-steroidal MRA and an SGLT2i concurrently in HF.”
InfluentialFernández‐Fernández, B., Górriz, J. L., Cuenca, A. M. C., Fácila, L., González-Moro, J. M. R., Maraver, M. P., & Ortíz, A. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.09.027 · Cited by 6
“Kidney Disease: Improving Global Outcomes risk map presenting the risk of all-cause death for each cell as well as the simplified nomenclature of mild, moderate, and severe CKD. 18 Individuals that may benefit from the nsMRA, finerenone according to the 2024 Kidney Disease: Improving Global Outcomes Guidelines on CKD…”
InfluentialAmeer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
“Both the public and medical professionals are interested in GLP-1 and GIP medications due to their potential to reduce the risk of chronic diseases and obesity-related health issues, along with their significant weight-loss benefits [ 73, 74 ].”
Galsgaard, K. D., Modvig, I. M., & Holst, J. J. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241062 · Cited by 4
Safety of Drugs in Breastfeeding Women With CKD
Parnizari, P., Hladunewich, M., & Zipursky, J. S. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.04.038 · Cited by 4
“113 There are limited data on the use of GLP1RAs during lactation.”
Wang, M., Dong, T., Lucero, M., Pan, W., Wang, X., Zhou, L., & Meng, Y. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.06.012 · Cited by 6
Ji, L., Jiang, H., Cheng, Z., Li, X., Pang, S., Zhang, Y., Qiu, W., MA, Q., Liu, Z., Wang, Y., et al. (2026) · Med · doi:10.1016/j.medj.2026.101063 · Cited by 4
Achieving equitable access to incretin-based therapies in cardiovascular care
Reddy, T. K., Villavaso, C. D., Pulapaka, A. V., & Ferdinand, K. C. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100455 · Cited by 11
Zhang, Z., Fu, C., Chai, Y., Gu, Y., Wu, X., Zhu, D., Lin, P., Yu, B., & Li, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02119-4 · Cited by 5
Cherney, D. Z. I., Alicic, R. Z., & Bonaca, M. P. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.01.010 · Cited by 7
Miao, Y., He, P., Wang, D.-Y., Yan, L., Cao, H., & Shao, F.-M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.112867 · Cited by 4
Khattab, M. A., Khalil, S. H. A., Bassyouni, A., Fawzy, F., Elgayar, A. H., Elebrashy, I., Elhadidy, K. E., Abdallah, K., El-Hefnawy, M. H., Halawa, M. R., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03091-7 · Cited by 5
“In FLOW, a randomized outcomes trial in adults with T2D and CKD, subcutaneous semaglutide significantly reduced the risk of clinically important kidney outcomes and death from cardiovascular causes versus placebo on top of standard care [34].”
Zhang, J., Peng, J., Yu, C., Ning, Y., Lin, W., Ni, M., Xie, Q., Yang, C., Liang, H., & Lin, M. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101265 · Cited by 5
“…[4] (e.g., dapagli fl ozin [5] and empagli fl ozin [6]) primarily function by reducing glucose reabsorption and sodium levels, while glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide [7] and semaglutide [8]) affect glucose regulation and exhibit anti-in fl ammatory effects [9].”
Combined sedentarism and high-fat diet induce early signs of kidney injury in C57BL/6J mice
Opurum, P. C., Decker, S. T., Stuart, D., Peterlin, A. D., Paula, V. L., Siripoksup, P., Drummond, M. J., Sánchez, A., Ramkumar, N., & Funai, K. (2025) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00259.2024 · Cited by 5
Efficacy of antiobesity medications for weight reduction in older adults: a systematic review
Chen, A. S., Hajduk, A. M., Grimshaw, A. A., Fried, T. R., Jastreboff, A. M., & Lipska, K. J. (2024) · Obesity · doi:10.1002/oby.24160 · Cited by 8
Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation
Eun, Y., Bong, S., Koh, H. Y., Trousdale, R. K., Cho, Y. M., Jang, Y., & Lee, S. (2026) · Neurology · doi:10.1212/wnl.0000000000218174 · Cited by 4
Hung, A. M., Beck, C., Greevy, R. A., Hackstadt, A. J., Elasy, T. A., & Roumie, C. L. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001033 · Cited by 4
Gut dysbiosis, low-grade inflammation, and renal impairment severity in elderly diabetic nephropathy
Shi, Y., Pan, Z., Zhang, J., Xue, L., & Li, M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.108245 · Cited by 6
Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes
Hamad, C. D., Wiener, J., Golzar, A., Hp, K., Henein, C., Kittredge, A. P., Su, G., Kaelber, D. C., Chan, L., Yeaman, M. R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.25141 · Cited by 7
A golden year of innovative kidney disease therapeutics
Ng, M. S. Y., & Hawley, C. M. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00916-z · Cited by 3
“In this trial, which enrolled 3,533 participants with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), semaglutide reduced the risk of major kidney disease events by 24% compared with placebo and had beneficial effects on slope of eGFR decline regardless of SGLT2 inhibitor use 4 .”
Chen, J., Chuang, M., Lai, H.-W., & Wu, V. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112339 · Cited by 7
What Is the Role of Sex Differences in Obesity-Associated Chronic Kidney Disease?
Sandino, J., González-García, C., Hernández-Velasco, P., Morales, E., & Sandino, J. (2025) · The Nephron journals/Nephron journals · doi:10.1159/000546354 · Cited by 3
Walking Further with GLP-1RAs: Lessons from the STRIDE Trial
Pantazopoulos, D., Papachristou, S., Vas, P. R. J., & Παπάνας, Ν. (2025) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346251385584 · Cited by 4
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.